The United States is at the forefront of advancements in adult malignant glioma therapeutics, supported by a strong ecosystem of leading research institutions, pharmaceutical companies, and specialized cancer treatment centers. The rising incidence of aggressive brain tumors, increasing investment in precision oncology, and growing adoption of targeted therapies and immunotherapies are driving...